Edition:
United Kingdom

Cardiome Pharma Corp (CRME.OQ)

CRME.OQ on NASDAQ Stock Exchange Capital Market

1.45USD
16 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.45
Open
$1.45
Day's High
$1.48
Day's Low
$1.45
Volume
5,432
Avg. Vol
19,170
52-wk High
$4.83
52-wk Low
$1.29

Chart for

About

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS... (more)

Overall

Beta: 0.96
Market Cap(Mil.): $67.53
Shares Outstanding(Mil.): 33.80
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.64
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Cardiome Announces Expanded Label For Aggrastat In China

* CARDIOME ANNOUNCES EXPANDED LABEL FOR AGGRASTAT® IN CHINA INCLUDING NEW STEMI INDICATION AND HIGH DOSE BOLUS REGIMEN

23 Jan 2018

BRIEF-Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia

* CARDIOME ANNOUNCES STRATEGIC LICENSING AGREEMENT TO COMMERCIALIZE AGGRASTAT IN RUSSIA

12 Dec 2017

BRIEF-Cardiome Q3 loss per share $0.20

* Q3 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S

14 Nov 2017

BRIEF-Cardiome Pharma commercially launches Xydalba in Sweden, Finland and Republic Of Ireland​

* Cardiome Pharma - has initiated commercial launch of Xydalba (dalbavancin hydrochloride) in Sweden, Finland and Republic Of Ireland​ Source text for Eikon: Further company coverage:

30 Oct 2017

BRIEF-Cardiome announces agreement with Basilea

* Cardiome announces agreement with Basilea for distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel

12 Sep 2017

BRIEF-Basilea says distribution agreement with Cardiome

* BASILEA ANNOUNCES DISTRIBUTION AGREEMENT WITH CARDIOME TO COMMERCIALIZE ANTIBIOTIC ZEVTERA/MABELIO (CEFTOBIPROLE) IN EUROPE AND ISRAEL

12 Sep 2017

BRIEF-Cardiome provides U.S. regulatory update for BRINAVESS

* Cardiome Pharma Corp - ‍FDA advised Cardiome that data package proposed by Cardiome would not be sufficient to support a resubmission of BRINAVESS NDA​

21 Aug 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $133.15 +1.92
Pfizer Inc. (PFE.N) $36.26 +0.55
Novartis AG (NOVN.S) CHF80.80 +1.18
Bayer AG (BAYGn.DE) €98.54 +1.15
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €64.50 +1.00
AstraZeneca plc (AZN.L) 4,739.50 +26.00
GlaxoSmithKline plc (GSK.L) 1,318.60 +18.20
Gilead Sciences, Inc. (GILD.OQ) $80.70 -0.85
Boston Scientific Corporation (BSX.N) $27.20 +0.11

Earnings vs. Estimates